Immune checkpoint inhibitors that target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1), and its ligand (PD-L1) display minimal or no activity as single agents or in combination with AR inhibitors in advanced prostate cancers (136–141). Here, AR is linked to prostate carcinoma.